Search Results

You are looking at 311 - 320 of 2,880 items for :

  • Refine by Access: All x
Clear All
Full access

Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price

Daniel Tobias Michaeli and Thomas Michaeli

-analyses was conducted for clinical trials with available outcome data. HRs for OS and PFS were meta-analyzed in all RCTs, as were RRs for tumor response. ORRs were meta-analyzed in all single-arm trials. Differences between HRs, RRs, and ORRs for breakthrough

Full access

Measuring Quality in Oncology: Challenges and Opportunities

Jessica K. DeMartino

Executive Summary Variations in the quality of cancer care are well documented. 1 , 2 A key element of quality monitoring is standardized measures of care. Quality measures may include both process and outcome measures. Process measurement is

Full access

Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers

Alison R. Walker and Guido Marcucci

is used to determine outcome risk and direct treatment strategies for patients, including allogeneic stem cell transplantation (SCT) in first complete remission. However, in 40% to 50% of patients, chromosome aberrations are not detected, making it

Full access

QIM19-134: Improving Access to Bone Marrow Transplant in the Community: The Memorial Sloan Kettering Cancer Alliance Shared Care Program

Craig Sauter, W. Jeffrey Baker, Elizabeth Rodriguez, Silvia Willumsen, Barbara Morcerf, Kristi Gafford, Jessica Kennington, Richard Korman, Peter Yu, David Pfister, and Sergio Giralt

patients with hematologic malignancies and the timing of a referral for transplant has significant impact on patient outcomes (National Marrow Donor Program, available at: https://bethematchclinical.org/transplant-indications-and-outcomes/additional-outcomes/timing-impact-on-outcomes

Full access

Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk

data, 14 , 15 whereas cyclophosphamide escalation did not lead to improved outcomes. 16 , 17 These results are informative but require updating as CMF, CAF, and FEC are inferior to third-generation chemotherapy regimens currently used in the adjuvant

Full access

The Integration of Chemotherapy and Surgery for Bladder Cancer

Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin

cancer outcomes after radical cystectomy . Urology 2003 ; 61 : 105 – 108 . 6 Konety BR Joslyn SA O'Donnell MA . Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the

Full access

Treatment of Acute Promyelocytic Leukemia for Older Patients

Thomas Prebet and Steven D. Gore

T he treatment of acute myeloid leukemia (AML) in older patients remains challenging. 1 Both disease- and patient-related factors unfavorably influence patient outcome, with a 2-year probability of overall survival of 10% to 15%. 2 Acute

Full access

VATS Versus Open Surgery for Lung Cancer Resection: Moving Toward a Minimally Invasive Approach

Jacob Klapper and Thomas A. D’Amico

. The thoracoscopic approach is oncologically equivalent to thoracotomy, while resulting in fewer complications, improved quality of life, shorter length of stay, and superior compliance with adjuvant therapies. 6 – 8 Oncologic Outcomes The

Full access

Reducing the Time From Initial Call to First Appointment: The Impact of Patient Access Redesign and a Nurse Navigation Program

Lori J. Goldstein, Bonnie J. Miller, Nancy Nicotera, and Delinda Pendleton

, FCCC’s performance has demonstrated a high level of concordance, based on findings from the NCCN Oncology Outcomes Database project benchmarking data in breast cancer. Access to the NCCN Breast Cancer Timing in Continuation and Transition of Care

Full access

HSR22-163: Real World Data and Independent Predictors of Clinical Outcomes with CDK Inhibitors in Metastatic ER+ Breast Cancer Patients

Priyanka Reddy, James Martin, and Alberto Montero